A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer

Journal of the National Cancer Institute

Volumn 95, Issue 17, 2003, Pages 1320-1330

  du Bois, Andreas ^a,b   Lück, Hans Joachim ^c   Meier, Werner ^d   Adams, Hans Peter ^e   Möbus, Volker ^f   Costa, Serban ^g   Bauknecht, Thomas ^h   Richter, Barbara ⁱ   Warm, Matthias ^j   Schröder, Willibald ^k   Olbricht, Sigrid ^l   Nitz, Ulrike ^m   Jackisch, Christian ⁿ   Emons, Günther ^o   Wagner, Uwe ^o   Kuhn, Walther ^p   Pfisterer, Jacobus ^q   von Maillot, K ^r   Lange, W ^r   Berg, D ^r   Schlicht, E ^r   Peterseim, H ^r   Elling, D ^r   Oney T ^r   Zimmermann, V ^r   Renziehausen, K ^r   Rohrmann, G ^r   Bach, H J ^r   Muller H ^r   Jager W ^r   Mickan, H ^r   Ackermann, R H ^r   Wernicke, K ^r   Czygan, P J ^r   Schulze Tollert, J ^r   Becker, H J ^r   Nast, J ^r   Kramb, P ^r   Kroner M ^r   Petru, E ^r   Carstensen, M ^r   Muller W ^r   Zippel, H H ^r   Hilfrich, J ^r   Herchenhein, W ^r   Mesrogli, M ^r   Schneider, A ^r   Deutsch, G ^r   Klock F K ^r   Maurer, W ^r   Sunter S ^r   Goppinger A ^r   Strigl, R ^r   Schuhmann, R ^r   Kuhndel K ^r   Fischer, D ^r   Leissner C ^r   Peters, F ^r   Niedner, W ^r   Peschke, K H ^r   Silz, T ^r   Schworer D ^r   Meinerz, W ^r   Kramer, D ^r   Richter, P ^r   Steichele, D F ^r   Krieger, P ^r   Lange, M ^r   Beck, T ^r   Friese, K ^r   Rother, D ^r   Heilmann, L ^r   Dietel, J ^r   Petri, E ^r   Meyer Grohbrugge J ^r   Jovanovic, V ^r   Robke, K ^r   Merkle, E ^r   Goretzlehner G ^r   Hanker, J P ^r   Karg, C ^r   Burkert, W ^r   Gruneberger A ^r   Flachsenberg, S ^r   more..

^a DR HORST SCHMIDT KLINIKEN   (Germany)

^b St Vincentius Hospital   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e Dr Horst Schmidt Kiliniken   (United Kingdom)

^f UNIVERSITY OF ULM   (Germany)

^g GOETHE UNIVERSITY   (Germany)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^j Department of Gynecology   (Germany)

^k RWTH AACHEN UNIVERSITY   (Germany)

^l UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^m HEINRICH HEINE UNIVERSITY   (Germany)

ⁿ UNIVERSITY OF MÜNSTER   (Germany)

^o PHILIPPS UNIVERSITY MARBURG   (Germany)

^p TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^q UNIVERSITY OF KIEL   (Germany)

^r NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; CARBOPLATIN; CIMETIDINE; CISPLATIN; CLEMASTINE; CORTICOSTEROID; DEXAMETHASONE; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; SEROTONIN 3 ANTAGONIST; ANTINEOPLASTIC AGENT;

ADVANCED CANCER; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG RESPONSE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEUROLOGIC DISEASE; OVARY CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; ADULT; AGED; DISEASE FREE SURVIVAL; GERMANY; MIDDLE AGED; MULTICENTER STUDY; OVARY TUMOR; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODEL; RISK; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; DISEASE-FREE SURVIVAL; FEMALE; GERMANY; HUMANS; MIDDLE AGED; ODDS RATIO; OVARIAN NEOPLASMS; PACLITAXEL; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODELS; QUALITY OF LIFE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0041329867     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Neijt JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Vriesendorp R, Kooyman CD, et al. Randomised trial comparing two combination chemotherapy regimens (Hexa-CAF vs. CHAP-5) in advanced ovarian carcinoma. Lancet 1984;2:594-600.
2. Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT, et al. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group study. Cancer 1986;57:1725-30.
3. Omura GA, Bundy BN, Berek JS, Curry S, Delgado G, Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1989;457-65.
4. Bertelsen K, Jakobsen A, Andersen JE, Ahrons S, Pedersen PH, Kiaer H, et al. A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma. Gynecol Oncol 1987; 28:161-9.
5. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996;334:1-6.
6. Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 2000;92:699-708.
7. Eisenhauer EA, ten Bokkel Huinink WW, Swenerton KD, Gianni L, Myles J, van der Burg ME, et al. European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 1994;12:2654-66.
8. International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet 2002;360:505-15.
9. Swenerton K, Jeffrey J, Stuart G, Roy M, Krepart G, Carmichael J, et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1992; 10:718-26.
10. Alberts DS, Green S, Hannigan EV, O'Toole R, Stock-Novack D, Anderson P, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol 1992;10:706-17.
11. du Bois A, Luck HJ, Bauknecht T, Mobus V, Bochtler H, Diergarten K, et al. Phase I/II study of the combination of carboplatin and paclitaxel as first-line chemotherapy in patients with advanced epithelial ovarian cancer. Ann Oncol 1997;8:355-61.
12. International Federation of Gynecology and Obstetrics. Changing in definitions of clinical staging for carcinoma of the cervix and ovary. Am J Obstet Gynecol 1987;156:263-4.
13. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56.
14. Jelliffe RW. Letter: Creatinine clearance: bedside estimate. Ann Intern Med 1973;79:604-5.
15. National Cancer Institute. Cancer Therapy Evaluation Program: Common Toxicity Criteria. Available at: http://ctep.cancer.gov/reporting/ctc.html.
16. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, et al. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 2000;47:13-47.
17. Ozols RF, Bundy BN, Fowler J, Clarke-Pearson D, Manuel R, Hartenbach E, et al. Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group trial (GOG 158) [abstract 1373]. Proc ASCO 1999;18:356a.
18. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
19. Fayers PM, Aaronson NK, Bjordal K, Curran D, Groenvold M, on behalf of the EORTC Quality of Life Study Group. The EORTC QLQ-C30 Scoring Manual. 2nd ed. Brussels (Belgium): European Organization for Research and Treatment of Cancer; 1999.
20. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva (Switzerland): World Health Organization; 1979 (Offset Publication No. 48). Available at http://whqlibdoc.who.int/publications/ 9241700483.pdf.
21. Fleiss JL. Statistical methods for rates and proportions. 2nd ed. New York (NY): John Wiley and Sons; 1981.
22. Blackwelder WC. "Proving the null hypothesis" in clinical trials. Control Clin Trials 1982;3:345-53.
23. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
24. Cox DR, Oakes D. Analysis of survival data. London (U.K.): Chapman and Hall; 1984.
25. Lown B, Wolf M. Approaches to sudden death from coronary heart disease. Circulation 1971;44:130-42.
26. Negrier S, Ollivier L, Di Stefano-Louineau D, Escudier B, Savary J, Lasset C, et al. Reliability of the response rate in oncology: analysis of the causes for variation. Bull Cancer 2000;87:927-34.
27. Neijt JP, Engelholm SA, Tuxen MK, Sorensen PG, Hansen M, Sessa C, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 2000;18: 3084-92.
28. du Bois A, Weber B, Pfisterer J, Goupil A, Wagner U, Barats J, et al. Epirubicin/Paclitaxel/Carboplatin (TEC) vs Paclitaxel/Carboplatin (TC) in first-line treatment of ovarian cancer FIGO stages IIB-IV. Interim results of an AGO-GINECO intergroup phase III trial [abstract]. Proc ASCO 2001; 20:202a.
29. Kristensen G, Vergote I, Stuart G, Izquiuerdo Delso M, Mirza R, Aavall-Liundquist F, et al. First-line treatment of ovarian cancer FIGO stages IIb-IV with paclitaxel/epirubicin/carboplatin (TEC) vs. paclitaxel/carboplatin (TC). Interim analysis of an NSGO-EORTC-NCIC CTG Gynecological Cancer Intergroup phase III trial [abstract]. Proc ASCO 2002;21: 202a.
30. Pfisterer J, Lortholary A, Kimmig R, Weber B, du Bois A, Bourgeois H, et al. Paclitaxel/carboplatin (TC) vs. paclitaxel/carboplatin followed by topotecan (TC-Top) in first-line treatment of ovarian cancer FIGO stages IIb-IV. Interim results of a Gynecologic Cancer InterGroup phase III trial of the AGO Ovarian Cancer Study Group and GINECO [abstract]. Proc ASCO 2003;22:446.